The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S26-S38 , April 2010

Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections

  • Hartmut Lode, MD, PhD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Hartmut M. Lode, MD, PhD, Research Center for Medical Studies (RCMS), Institute for Clinical Pharmacology, Charité University of Medicine of Berlin, Hohenzollerndamm 2, D-10717 Berlin, Germany

References 

  1. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858–1866
  2. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47:735–743
  3. Tulkens P, Van Bambeke F. Fluoroquinolone selection: appropriate benefit-risk profiles. Poster presented at the Fifth Forum on Respiratory Tract Infections; February 5, 2009; Barcelona, Spain.
  4. Levine JG, Szarfman A. Data mining analysis of multiple antibiotics in AERS. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1-01-06-FDA-Levine.pptAccessed May 26, 2009
  5. Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis. 2008;8:83–85
  6. Noel GJ. A review of levofloxacin for the treatment of bacterial infections. Clin Med Ther. 2009;1:433–458
  7. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy. 2001;47(suppl 3):32–37
  8. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(suppl 2):S144–S157
  9. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36:1404–1410
  10. Jagose JT, McGregor DR, Nind GR, Bailey RR. Achilles tendon rupture due to ciprofloxacin. N Z Med J. 1996;109:471–472
  11. Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J. 2000;93:488–491
  12. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324:1306–1307
  13. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy. 2005;25:1296–1302
  14. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352–1361
  15. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996;117:372–376
  16. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy. 2000;20(pt 2):76S–86S
  17. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32:359–378
  18. Zambon A, Polo FH, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf. 2009;32:159–167
  19. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest. 2005;128:3398–3406
  20. Samaha FF. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med. 1999;107:528–529
  21. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci. 2004;29:63–71
  22. Avelox [prescribing information]. Kenilworth, NJ: Schering-Plough Corp; 2008;
  23. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292–303
  24. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol. 2006;11:52–56
  25. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol. 1998;12:70–76
  26. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones—the pharmacokinetic standpoint. Chemotherapy. 2001;47(suppl 3):24–31
  27. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 2000;22:798–817
  28. Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004;44:464–473
  29. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol. 2009;49:674–683
  30. Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol. 2008;48:799–811
  31. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008;48:726–733
  32. Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol. 2008;65(suppl 1):68–75
  33. Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther. 2008;30:260–270
  34. Koide T, Shiba M, Tanaka K, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J. 2008;1:409
  35. Altin T, Ozcan O, Turhan S, et al. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol. 2007;23:907–908
  36. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother. 2007;41:336–340
  37. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992;36:942–948
  38. Zhang L, Wei MJ, Zhao CY, Qi HM. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008;29:1507–1514
  39. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004;76:598–606
  40. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998;42:1831–1836
  41. Salvo F, Polimeni G, Cutroneo PM, et al. Allergic reactions to oral drugs: a case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacol Res. 2008;58:202–207
  42. Bartlett JG, Perl TM. The new Clostridium difficile—what does it mean?. N Engl J Med. 2005;353:2503–2505
  43. Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359:1932–1940
  44. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–280
  45. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449
  46. Pépin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–1260
  47. Spigaglia P, Barbanti F, Mastrantonio P, et al. for the European Study Group on Clostridium difficile (ESGCD) Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol. 2008;57:784–789
  48. Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J. 1997;16:427–431
  49. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;91:40S–45S
  50. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol. 1992;13:357–368
  51. Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf. 1993;8:350–364
  52. Yanagihara K, Izumikawa K, Higa F, et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med. 2009;48:527–535
  53. Paris R, Confalonieri M, Dal Negro R, et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother. 2008;20:77–86
  54. Kuzman I, Dakovic-Rode O, Oremus M, Banaszak AM. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J Chemother. 2005;17:636–642
  55. Snyman JR, Schoeman HS, Grobusch MP, et al. Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin Drug Investig. 2009;29:265–274
  56. Lee PI, Wu MH, Huang LM, Chen JM, Lee CY. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect. 2008;41:54–61
  57. Bonvehi P, Weber K, Busman T, Shortridge D, Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Investig. 2003;23:491–501
  58. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004;54:515–523
  59. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285–295
  60. Biaxin [prescribing information]. North Chicago, IL: Abbott Laboratories; 2008;
  61. Saito H, Fukasawa Y, Otsubo Y, Yamada K, Sezaki H, Yamashita S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm Res. 2000;17:761–765
  62. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408–414
  63. Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999;39:501–504
  64. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18:621–649xi
  65. Guerriero SE, Ehrenpreis E, Gallagher KL. Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy. 1997;17:1035–1037
  66. Neu HC, Wilson AP, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother. 1993;5:67–93
  67. Salvo F, De Sarro A, Caputi AP, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009;8:111–118
  68. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521
  69. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327–1332
  70. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71–80
  71. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut. 1992;33:368–371
  72. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856
  73. Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60:121–126
  74. Martinez-Mir I, Ferrer JM, Palop V, Estan L, Rubio E, Morales-Olivas FJ. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?. Pharmacoepidemiol Drug Saf. 1996;5:247–254
  75. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 1999;48:839–846
  76. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother. 2003;37:367–370
  77. Kelly M, Moran J, Byrne S. Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: a case report. Am J Geriatr Pharmacother. 2005;3:266–269
  78. Wood GD, Deeble T. Warfarin: dangers with antibiotics. Dent Update. 1993;20:350;352-350, 353
  79. Amoxil [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2008;
  80. Easton J, Noble S, Perry CM. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs. 2003;63:311–340
  81. Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37:22–26
  82. Mitropoulos IF, Rotschafer JC, Rodvold KA. Adverse events associated with the use of oral cephalosporins/cephems. Diagn Microbiol Infect Dis. 2007;57(suppl 3):67S–76S
  83. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med. 1990;88:38S–44S
  84. Neu HC. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol. 1990;30:396–403
  85. Bijie H, Kulpradist S, Manalaysay M, Soebandrio A. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. J Chemother. 2005;17:3–24
  86. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007;136:340–347
  87. Fonacier L, Hirschberg R, Gerson S. Adverse drug reactions to a cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc. 2005;26:135–141
  88. Suprax [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; 2003;
  89. Wu DH. A review of the safety profile of cefixime. Clin Ther. 1993;15:1108–1119
  90. Gooch WM, Philips A, Rhoades R, Rosenberg R, Schaten R, Starobin S. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J. 1997;16(suppl 2):S21–S24
  91. Guay DR. Cefdinir: an expanded-spectrum oral cephalosporin. Ann Pharmacother. 2000;34:1469–1477
  92. Guay DR. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther. 2002;24:473–489
  93. Neu HC. Cephalosporins—cefotaxime 10 years later, a major drug with continued use. Infection. 1991;19(suppl 6):S309–S315
  94. Goddard JK, Janning SW, Gass JS, Wilson RF. Cefuroxime-induced acute renal failure. Pharmacotherapy. 1994;14:488–491
  95. Nahata MC, Barson WJ. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985;19:900–906
  96. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf. 2008;7:515–523
  97. Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34:1146–1149
  98. Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion. 2004;44:1033–1040
  99. Chonmaitree T, Congeni BL, Munoz J, Rakusan TA, Powell KR, Box QT. Twice daily ceftriaxone therapy for serious bacterial infections in children. J Antimicrob Chemother. 1984;13:511–516
  100. Committee for Proprietary Medicinal Products (CPMP). European Agency for the Evaluation of Medicinal Products (EMEA). [EMEA Website.] Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. London: EMEA; April 22, 2004 http://www.emea.europa.eu/pdfs/human/ewp/055895en.pdfAccessed April 23, 2009
  101. US Food and Drug Administration. MedWatch: the FDA Safety Information and Adverse Event Reporting Program. [FDA Web site.] http://www.fda.gov/Safety/MedWatch/default.htmAccessed November 2, 2009
  102. US Food and Drug Administration. Adverse Event Reporting System (AERS). [FDA Web site.] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htmAccessed April 23, 2009
  103. US Food and Drug Administration. Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)] [FDA alert]. [FDA Web site.] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htmAccessed June 23, 2009
  104. US Food and Drug Administration. Telithromycin (marketed as Ketek) information. [FDA Web site.] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htmAccessed June 23, 2009

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(10)00099-9

doi: 10.1016/j.amjmed.2010.02.004

The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S26-S38 , April 2010

Article Tools

* Image Usage & Resolution